SMAD4 and colorectal carcinoma: Using a biologically informed perspective to derive a SMAD4‐modulated gene profile, we validated a prognostic model to identify low‐ and high‐risk groups of stage II/III CRC patients on the basis of expression of SMAD4‐modulated genes.